説明
The Lentivirus Concentration Kit contains a 5× concentration solution that enables simple and rapid concentration of all types of lentiviral particles. The procedure is straightforward: mix the 5× concentration solution with lentivirus-containing supernatant at the specified ratio, incubate briefly, and then centrifuge using a standard centrifuge to obtain concentrated lentiviral particles. The recovery rate is over 90%, and the viral titer can be increased up to 100-fold.
Features
- Rescue low-titer viral particles, up to 100 fold
- Simple mix and centrifuge, no need for ultracentrifugation
- Easily scaled up for large volumes
Components
Components No. |
Name |
41101ES50 |
41101 |
Lentivirus Concentration Solution |
50 mL |
Shipping and Storage
This product should be stored at -25~-15℃ for 1 year.
Application
Lentivirus Production
Documents:
Safety Data Sheet
Manuals
41101_Manual_Ver.EN20250819.pdf
Citations & References
[1] He Y, Gallman AE, Xie C, et al. P2RY8 variants in lupus patients uncover a role for the receptor in immunological tolerance. J Exp Med. 2022;219(1):e20211004. doi:10.1084/jem.20211004(IF:14.307)
[2] Peng J, Pan J, Wang H, Mo J, Lan L, Peng Y. Morphine-induced microglial immunosuppression via activation of insufficient mitophagy regulated by NLRX1. J Neuroinflammation. 2022;19(1):87. Published 2022 Apr 12. doi:10.1186/s12974-022-02453-7(IF:8.322)
[3] Guo Y, Zhao J, Huang R, Xu T, Zhou K, Zheng L. Scalable Dual-Fluorescence Assay for Functional Interpretation of HNF-4α Missense Variants. Front Endocrinol (Lausanne). 2022;13:812747. Published 2022 Feb 14. doi:10.3389/fendo.2022.812747(IF:5.555)
[4] Fan J, He Q, Jin Z, Chen W, Huang W. A novel phosphoester-based cationic co-polymer nanocarrier delivers chimeric antigen receptor plasmid and exhibits anti-tumor effect. RSC Adv. 2018;8(27):14975-14982. Published 2018 Apr 19. doi:10.1039/c8ra02133c(IF:2.936)
支払いとセキュリティ
お支払い情報は安全に処理されます。 クレジットカードの詳細を保存したり、クレジットカード情報にアクセスすることはありません
問い合わせ
あなたも好きかもしれません
よくある質問
この製品は研究目的のみに使用され、人間や動物の治療や診断に使用することを意図したものではありません。製品とコンテンツは、
特定のアプリケーションでは、追加のサードパーティの知的財産権が必要になる場合があります。